- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Hossein Kazemi on Identifying Eligible Patients With MM for De-escalation
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses emerging tools to use to identify patients with multiple myeloma for de-escalating treatment.
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, speaks about emerging tools in patient assessment for de-escalation treatment for individuals with multiple myeloma.
Transcript
Are there emerging diagnostic tools for treatment de-escalation that are not widely used in practice yet that you’re expecting will help better identify patients?
It's still in research phase, in trial phase, but I'm eagerly looking forward to mass spectrometry, which can be done from peripheral blood that does not need bone marrow biopsy that makes [minimal residual disease] MRD assessment much, much easier. We can test for it more frequently, without putting the patient through the discomfort of bone marrow biopsy. Of course, it's not something that's FDA approved at this time, but I'm eagerly following the updates about that.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
